16 September 2026 editorial review · Trial
Precision ATG with or without verapamil in new-onset T1D: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Baseline trial evidence review: M–S
Outcome: No additional discrepancy identified in the reviewed summary/design/endpoint and eligibility fields. Existing sponsor or historical claims are not all independently certified by this protocol comparison.
Registry: NCT06455319. Endpoint reviewed: AUC C-peptide between ATG and placebo values (12 Months); Change in 2-hr MMTT AUC C-peptide (6 months). Eligibility reviewed: Age 6 Years to 35 Years; diagnosis/stage, prior therapy and key biomarker criteria compared with site summary. Full exclusions remain in the registry. Literature access limit: No usable primary abstract was independently recovered for this record in this pass. Current registry protocol was the main source; detailed sponsor or conference data remain dependent on the cited source and were not fully reverified.